Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. 
Concurrent vinablastine-based radiochemotherapy was evaluated in 84 bladder-cancer patients.  It was effective in more than half: tumour-specific survival (51% 9-year), local control rate (55% 9-year).  The drawback was the impaired function of the bladder (9-year prevalence SOMA G3-4 symptoms: 66%), indicating the need for treatment aimed at reducing chronic morbidity.